The estimated Net Worth of Sanjay Shukla is at least $961 millier dollars as of 31 May 2024. Dr Shukla owns over 20,000 units of Atyr Pharma Inc stock worth over $259,441 and over the last 5 years he sold LIFE stock worth over $0. In addition, he makes $702,046 as Pres et CEO & Director at Atyr Pharma Inc.
Dr has made over 14 trades of the Atyr Pharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of LIFE stock worth $36,200 on 31 May 2024.
The largest trade he's ever made was buying 20,000 units of Atyr Pharma Inc stock on 31 May 2024 worth over $36,200. On average, Dr trades about 6,563 units every 75 days since 2020. As of 31 May 2024 he still owns at least 136,548 units of Atyr Pharma Inc stock.
You can see the complete history of Dr Shukla stock trades at the bottom of the page.
Dr. Sanjay S. Shukla is the Pres, CEO & Director at Atyr Pharma Inc.
As the Pres et CEO & Director of Atyr Pharma Inc, the total compensation of Dr Shukla at Atyr Pharma Inc is $702,046. There are no executives at Atyr Pharma Inc getting paid more.
Dr Shukla is 49, he's been the Pres et CEO & Director of Atyr Pharma Inc since . There are 11 older and 1 younger executives at Atyr Pharma Inc. The oldest executive at Atyr Pharma Inc is Paul Schimmel, 79, who is the Independent Director.
Sanjay's mailing address filed with the SEC is 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO, CA, 92121.
Over the last 16 years, insiders at Atyr Pharma Inc have traded over $27,288,922 worth of Atyr Pharma Inc stock and bought 966,653 units worth $5,761,237 . The most active insiders traders include James C Blair, Gregory T Lucier et Craig J Mundie. On average, Atyr Pharma Inc executives and independent directors trade stock every 22 days with the average trade being worth of $34,257. The most recent stock trade was executed by Jill Marie Broadfoot on 31 May 2024, trading 5,000 units of LIFE stock currently worth $8,950.
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation
Atyr Pharma Inc executives and other stock owners filed with the SEC include: